De-risking Drug Development with Digital

Moving away from traditional, costly, time-consuming and often unsuccessful R&D methods, innovative companies are looking to AI and machine learning to reduce costs and improve success rates in drug development. 

This session will explore the different types of AI currently being used by Pharma companies, projects that identify novel pathways, targets and biomarkers and discuss the challenges of biometric data security, and how companies can work alongside existing regulations.  

 Discussion Points   

• What are the different types of Artificial Intelligence and use cases?  
• A look at current regulations and how to make them work for you    
• Federated learning in AI development   
• How biocatalysts are reshaping the synthesis of chemical entities.  
• The power of 3D molecular modeling  

In Partnership with AAPS